Missed Cellectricon at the ELRIG meeting on Advances in Cell-based Screening? There is still a chance to receive a copy of our poster stemming from a highly interesting drug discovery program, led by the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, for the development of small molecule activators of NaV1.2 as a therapeutic strategy for autism spectrum disorder.

Amongst other things, the poster showcases the design and establishment of a novel HTS assay based on “spiking HEK cells” and Cellectricon’s optical electrophysiology platform. The approach, which combines physiological stimulation with high-capacity screening was an integral part in the screening cascade all the way to hit validation.

Reach out to us if you would like to learn more or receive a copy of the poster!